Castle Biosciences (NASDAQ:CSTL) Insider Sells 2,546 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 2,546 shares of Castle Biosciences stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $30.68, for a total transaction of $78,111.28. Following the sale, the insider owned 21,479 shares in the company, valued at approximately $658,975.72. This represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 0.2%

NASDAQ CSTL traded up $0.07 on Thursday, hitting $30.47. The company’s stock had a trading volume of 833,433 shares, compared to its average volume of 407,908. The company’s 50-day moving average is $23.38 and its 200 day moving average is $26.23. The firm has a market cap of $930.86 million, a PE ratio of -46.17 and a beta of 0.98. Castle Biosciences, Inc. has a 1-year low of $17.72 and a 1-year high of $44.28. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. The business had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. As a group, analysts predict that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Trading of Castle Biosciences

Several hedge funds have recently modified their holdings of CSTL. Federated Hermes Inc. bought a new position in Castle Biosciences during the fourth quarter worth $26,000. Kemnay Advisory Services Inc. acquired a new position in shares of Castle Biosciences during the fourth quarter valued at about $35,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after purchasing an additional 297 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Castle Biosciences by 140.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock valued at $68,000 after buying an additional 1,022 shares during the period. Finally, CWM LLC increased its position in Castle Biosciences by 20.5% in the 4th quarter. CWM LLC now owns 2,302 shares of the company’s stock valued at $90,000 after buying an additional 391 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Trending Headlines about Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth prospects and implies meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle’s latest quarterly performance exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the loss of $0.07 per share was narrower than the expected $0.41 loss. The results support the view that operating performance is improving, although the company remains unprofitable.
• Positive Sentiment: Wall Street sentiment remains generally favorable, with an overall “Moderate Buy” consensus rating and an average price target of approximately $42. Institutional investors and hedge funds own about 92.6% of outstanding shares, while several funds recently increased their positions.
• Negative Sentiment: Several Castle Biosciences insiders sold shares. Derek J. Maetzold sold more than 39,000 shares across August 4–5, COO Kristen Oelschlager sold 8,586 shares, and Tobin W. Juvenal also reported a sale. The transactions reduced the executives’ holdings and could weigh on sentiment, particularly following the stock’s recent strength. However, the sales were conducted under pre-arranged Rule 10b5-1 plans, making them a less decisive bearish signal than discretionary selling. Castle Biosciences insider sales filing

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CSTL. BTIG Research raised their price target on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday. KeyCorp set a $35.00 target price on shares of Castle Biosciences in a research note on Friday, May 29th. Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 26th. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.